Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

115 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia.
Manco-Johnson MJ, Abshire TC, Shapiro AD, Riske B, Hacker MR, Kilcoyne R, Ingram JD, Manco-Johnson ML, Funk S, Jacobson L, Valentino LA, Hoots WK, Buchanan GR, DiMichele D, Recht M, Brown D, Leissinger C, Bleak S, Cohen A, Mathew P, Matsunaga A, Medeiros D, Nugent D, Thomas GA, Thompson AA, McRedmond K, Soucie JM, Austin H, Evatt BL. Manco-Johnson MJ, et al. Among authors: leissinger c. N Engl J Med. 2007 Aug 9;357(6):535-44. doi: 10.1056/NEJMoa067659. N Engl J Med. 2007. PMID: 17687129 Free article. Clinical Trial.
Risk factors for infection with HBV and HCV in a largecohort of hemophiliac males.
Soucie JM, Richardson LC, Evatt BL, Linden JV, Ewenstein BM, Stein SF, Leissinger C, Manco-Johnson M, Sexauer CL; Hemophilia Surveillance System Project Investigators. Soucie JM, et al. Among authors: leissinger c. Transfusion. 2001 Mar;41(3):338-43. doi: 10.1046/j.1537-2995.2001.41030338.x. Transfusion. 2001. PMID: 11274587
End-stage liver disease in persons with hemophilia and transfusion-associated infections.
Goedert JJ, Eyster ME, Lederman MM, Mandalaki T, De Moerloose P, White GC 2nd, Angiolillo AL, Luban NL, Sherman KE, Manco-Johnson M, Preiss L, Leissinger C, Kessler CM, Cohen AR, DiMichele D, Hilgartner MW, Aledort LM, Kroner BL, Rosenberg PS, Hatzakis A. Goedert JJ, et al. Among authors: leissinger c. Blood. 2002 Sep 1;100(5):1584-9. Blood. 2002. PMID: 12176875 Free article. Clinical Trial.
The application of bypassing-agent prophylaxis in haemophilia A patients with inhibitors: a meeting report.
Valentino LA, Carcao M, Mathew P, Leissinger CA, Berntorp E, Blanchette V, Escuriola-Ettingshausen C, Ewenstein B, Ewing N, Gringeri A, Hoots WK, Negrier C. Valentino LA, et al. Among authors: leissinger ca. Haemophilia. 2009 Jul;15(4):959-65. doi: 10.1111/j.1365-2516.2008.01953.x. Epub 2009 Mar 23. Haemophilia. 2009. PMID: 19320750 No abstract available.
Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor.
Flood VH, Gill JC, Morateck PA, Christopherson PA, Friedman KD, Haberichter SL, Branchford BR, Hoffmann RG, Abshire TC, Di Paola JA, Hoots WK, Leissinger C, Lusher JM, Ragni MV, Shapiro AD, Montgomery RR. Flood VH, et al. Among authors: leissinger c. Blood. 2010 Jul 15;116(2):280-6. doi: 10.1182/blood-2009-10-249102. Epub 2010 Mar 15. Blood. 2010. PMID: 20231421 Free PMC article.
115 results